NZ Colorectal Oncology Research Review Issue 33

In this issue:
  -  Faecal immunochemical and blood tests for CRC risk stratification
  -  Chromosome 18q11.2-q12.1 marker for bevacizumab use in mCRC
  -  Stop-gain mutation in GXYLT1 promotes CRC metastasis
  -  Pembrolizumab for MSI-H or dMMR mCRC
  -  Neoadjuvant chemotherapy for colorectal peritoneal metastases
  -  Endoscopic mucosal resection of large non-pedunculated colorectal polyps
  -  Trough regorafenib levels and OS in chemorefractory mCRC
  -  Antibiotic consumption and colon and rectal cancer development
  -  Bevacizumab + chemotherapy for brain-gut peptides, intestinal flora, and oxidative stress
  -  Multi-peptide vaccine + maintenance therapy in mCRC

Please login below to download this issue (PDF)